U.S. and Israel to align drug approvals—without explicit privacy safeguards
H.R. 661 — MIRACLE Medical Technology Act of 2025 · Filed by Vern Buchanan (R-FL) · 3 cosponsors · Introduced Jan 23, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a formal U.S.-Israel partnership program to jointly develop and commercialize medical devices, pharmaceuticals, biologics, and digital health technologies. The Secretary of Health and Human Services will coordinate with Israeli counterparts to align regulatory standards, share health data for research, establish joint manufacturing facilities, and accelerate product approvals—with $8 million annually authorized through 2030.
Why we flagged it
The bill's core function is to establish a formal government-to-government framework for aligning U.S. and Israeli regulatory standards, facilitating technology transfer, and enabling joint commercialization of medical products—not a routine health initiative. The emphasis on 'regulatory harmonization,' 'intellectual property protection,' and 'commercialization frameworks' reveals a private-sector-oriented partnership structure.
What the text implies
- Health data sharing with Israel's Ministry of Health is authorized without explicit congressional oversight of privacy safeguards, data residency, or cybersecurity standards beyond vague language about 'encouraging' them.
- Regulatory harmonization with Israeli authorities may lower FDA approval standards for biologics and devices if mutual recognition agreements are pursued, potentially accelerating products to market without full U.S. safety review.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical companies (U.S. and Israeli); medical device manufacturers; biologics/biotech firms